Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 65.00
Bid: 63.00
Ask: 67.00
Change: -0.50 (-0.76%)
Spread: 4.00 (6.349%)
Open: 65.50
High: 65.50
Low: 65.00
Prev. Close: 65.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Recommended Offer for Anker

24 Aug 2005 12:11

Torex Retail PLC24 August 2005 Torex Retail Plc24 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR ANKER PLC Offer Wholly Unconditional and Compulsory Acquisition of Outstanding Anker Shares The Board of Torex Retail Plc ("Torex Retail") announces that the offer (the"Offer") made by UBS Investment Bank on behalf of Torex Retail for Anker Plc("Anker") has today become wholly unconditional. As at 3.00 p.m. on 23 August 2005, Anker had received valid acceptances of theoffer in respect of a total of 41,177,970 Anker Shares, representingapproximately 99.02 per cent. of the existing issued share capital of Anker. As at 3.00 p.m. on 23 August 2005, valid acceptance of the Offer in relation to8,292,325 Anker Shares, representing 19.94 per cent. of the existing issuedordinary share capital of Anker, had been received electing for the basic termsof the Offer, valid acceptances of the Offer in relation 26,192,409 AnkerShares, representing approximately 62.99 per cent. of the existing issuedordinary share capital of Anker, had been received electing for additional cashunder the Mix and Match Facility and valid acceptances of the Offer in relation6,693,236 Anker Shares, representing approximately 16.10 per cent. of theexisting issued ordinary share capital of Anker, had been received electing foradditional New Torex Retail Shares under the Mix and Match Facility. Prior to the posting of the Offer Document on 22 July 2005, Torex Retail hadreceived irrevocable undertakings or letters of intent from the Anker Directorsand certain other Anker Shareholders to accept or procure the acceptance of theOffer in respect of, in aggregate, 31,347,988 Anker Shares, representingapproximately 75.4 per cent. of the existing issued ordinary share capital ofAnker. Included in the valid acceptances of the Offer set out above areacceptances in respect of 31,347,988 Anker Shares, representing approximately75.4 per cent. of the existing issued ordinary share capital of Anker, receivedpursuant to such irrevocable undertakings and letters of intent. Neither Torex Retail nor any persons deemed to be acting in concert with it forthe purposes of the Offer owned any Anker Shares (or rights over such shares) on29 June 2005 (being the last dealing day prior to the commencement of the Offerperiod) nor has Torex Retail nor any person deemed to be acting in concert withit for the purposes of the Offer acquired or agreed to acquire any Anker Shares(or rights over such shares) during the Offer period other than by way ofacceptances of the Offer. Compulsory Acquisition and cancellation of listing As described in the Offer Document, as and when Torex Retail receivesacceptances under the Offer in respect of, and/or otherwise acquired 90 percent. or more of the Anker Shares to which the Offer related, Torex Retailintends to exercise its rights pursuant to the provisions of sections 428 to430F of the Companies Act 1985 to acquire compulsorily Anker Shares in respectof which acceptances have not been received. Accordingly, Torex Retail is today issuing notices under s.429 of the CompaniesAct 1985 to Anker Shareholders who have not yet accepted the Offer that it nowintends to exercise its rights to acquire compulsorily all of those Anker Sharesstill outstanding at the expiry of the requisite notice period. In themeantime, the Offer remains open for acceptance until further notice, althoughthe Mix and Match Facility is now closed. Notice has also been sent to the Board of Anker requesting that the AnkerDirectors make an application to AIM for cancellation of the admission totrading of Anker Shares on AIM. It is expected that such cancellation willbecome effective after 20 clear business days following this announcement on the20 September 2005. For Anker Shares held in certificated form, Forms of Acceptance should becompleted, signed and returned in accordance with instructions set out in theOffer Document and in the Form of Acceptance, so as to be received as soon aspossible. For Anker Shares held in uncertificated form, an Electronic Acceptanceshould be made in accordance with instructions set out in the Offer Document sothat the TTE Instruction settles as soon as possible. Settlement of consideration Settlement of consideration to which any Anker Shareholder is entitled will beeffected: (i) in the case of acceptances received (complete in all respects) by23 August 2005 within 7 days of this date; or (ii) in the case of acceptancesreceived (complete in all respects) after 23 August 2005 but while the Offerremains open, within 7 days of such receipt. Terms defined in the offer document dated 22 July 2005 (the "Offer Document")shall, unless the context requires otherwise, have the same meanings in thisannouncement. EnquiriesTorex Retail Plc Telephone: 01295 753313Richard Thompson / Nigel Horn UBS Investment Bank Telephone: 0207 567 8000Ben Robertson / Jackie Lee This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th Mar 20164:35 pmRNSPrice Monitoring Extension
11th Mar 20163:02 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Mar 20167:00 amRNS510k market clearance granted for SurgiPureT XD
9th Mar 20167:00 amRNSFurther Medicare Coverage for DermaPure®
11th Feb 20167:00 amRNSVP, Orthopaedic, Inc. North America appointed
3rd Feb 20167:00 amRNSDermaPure to be Showcased in Nine Posters at SAWC
26th Jan 201612:21 pmRNSJoint Venture Agreement
25th Jan 20167:00 amRNSHardman & Co Research Report
20th Jan 20167:00 amRNSDermaPure® breaks through $1m sales mark
19th Jan 20167:00 amRNSAppointment of Non-Executive Director
18th Jan 20167:00 amRNSOrthoPureT XM clinical trial enrolment completed
23rd Dec 201512:40 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
4th Dec 20157:00 amRNSOrthoPureT XT implants successfully undertaken
5th Nov 20154:42 pmRNSIssue of equity and total voting rights
26th Oct 20157:00 amRNSIssue of equity and total voting rights
23rd Oct 20157:49 amRNSNon-Executive Director Share Purchase
14th Oct 20154:09 pmRNSEdison initiates coverage of Tissue Regenix
12th Oct 20157:00 amRNSInterim Results
4th Sep 201510:11 amRNSNotice of Interim Results and Capital Markets Day
30th Jul 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
22nd Jul 20157:00 amRNSAdditional US regional distribution agreement
26th Jun 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure®
12th Jun 201512:43 pmRNSResult of AGM
1st Jun 20159:17 amRNSDermaPure saves 18 year old's leg from frost bite
21st May 20159:51 amRNSHolding(s) in Company
20th May 20157:00 amRNSEmployee SAYE Share Plan
12th May 20157:00 amRNSDeferred Annual Bonus Award
11th May 20157:00 amRNSFinal Results
11th May 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
5th May 20157:02 amRNSUS regional distribution agreement signed
1st May 20154:01 pmRNSHolding(s) in Company
29th Apr 20157:01 amRNSDermaPure US Clinical data to be presented at SAWC
28th Apr 20157:00 amRNSOrthoPureT XT (Tendon) UK Clinical Trial Approval
9th Mar 20152:05 pmRNSNotice of Preliminary Results
6th Mar 20157:09 amRNSDermaPure gains Medicare coverage approval
5th Mar 20151:36 pmRNSIssue of equity and total voting rights
5th Mar 20151:18 pmRNSIssue of equity and total voting rights
5th Mar 201510:38 amRNSUK Patient has world's first OrthoPure XM implant
26th Feb 201510:43 amRNSResignation of Dr Alison Fielding
9th Feb 201512:05 pmRNSResult of General Meeting
4th Feb 201510:59 amRNSIssue of equity and total voting rights
22nd Jan 201511:13 amRNSResults of Placing
22nd Jan 20157:00 amRNSProposed placing of new Ordinary Shares
1st Dec 20149:45 amRNSHolding(s) in Company
28th Nov 20149:45 amRNSHolding(s) in Company
25th Nov 20148:15 amRNSNotice of allowance for US meniscus patent
5th Nov 20147:00 amRNSTissue Regenix gains Medicare and Medicaid Q code
29th Oct 20147:00 amRNSInterim Results
22nd Oct 20149:01 amRNSInterim Results and Capital Markets Day
20th Oct 201410:19 amRNSdCELL(R) presented at prestigious EACTS congress

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.